The Cancer Center (CORE) Support Grant (CCSG), will provide the necessary financial support that will assure quality administration of major programs in interdisciplinary basic and clinical cancer research, cancer education and training, cancer diagnosis and therapy, and community outreach. It is the intent of the OSUCCC to translate its own and other laboratories' observations into applicable clinical usage and to communicate existing and newly developed therapies, diagnostic procedures and prevention methods to the Ohio Valley Region. The CCSG will provide salary support for directors of vital programs and for key investigators necessary for further Center development. These individuals will collectively help to: (1) Optimally utilize and integrate the cancer efforts extant within the seven colleges at OSU engaged in cancer research; (2) Develop new programs, pilot studies and demonstration projects in cancer research, education, diagnosis and therapy within the OSUCCC and at community levels; (3) Encourage, aid, support and integrate community-run programs which are aimed to meet the needs of the respective areas; (4) Develop interdisciplinary activities between clinical and basic scientists to affect the translation process from laboratory to clinical application; (5) Communicate approved new developments in cancer diagnosis, therapy and rehabilitation to cooperating institutions throughout the Ohio Valley Region; (6) Establish effective cooperation with other existing and developing cancer centers including the National Cancer Institute. The OSUCCC will undergo significant development during the next five years that should culminate in solidification of research programs and development of an effective Cancer Control program for the region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-12
Application #
3101524
Study Section
(SRC)
Project Start
1977-07-01
Project End
1986-09-29
Budget Start
1985-07-01
Budget End
1986-09-29
Support Year
12
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Overall Medical
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications